RecruitingPhase 2NCT07636811
81
studies recruiting now
as of 7 Sept 2026
483
studies registered in total
as of 7 Sept 2026
6
countries with a recruiting site
as of 7 Sept 2026
25 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07598643
Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1
RecruitingPhase 4NCT07280468
Endotype DIrected Treatment for OSA in Down Syndrome
RecruitingPhase 2NCT04546399
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingNot applicableNCT07785011
Effect of Sensory Integration on Gross and Balance on Children With Down Syndrome
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 81 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Down syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Down syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Leucovorin Calcium (Leucovorin calcium)
Phase 3Leucovorin
Phase 3Thyroid (Nature)
Phase 3Donepezil Hydrochloride (Adlarity)
Phase 3Dextrothyroxine
Phase 2Basmisanil
Phase 2Bumetanide (Betinex)
Phase 2Scyllitol
+ 7 more in development
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).